Hepatoprotective Activity Screening Service

The hepatoprotective activity screen is an advanced technology used to evaluate the potential of marine glycans and glycoproteins to provide hepatoprotective activity, helping to protect the liver from damage. Many marine glycans and glycoproteins have hepatoprotective activity, such as algal glycoprotein, marine chitosan, marine chondroitin sulfate, etc.

At CD BioGlyco, we provide comprehensive Bioactivity Analysis of Marine Glycan&Glycoprotein, including but not limited to:

• Antioxidant Activity Screening Service
• Antimicrobial Activity Screening Service
• Antiviral Activity Screening Service
• Anti-blood Clotting Activity Screening Service
• Antitumor Activity Screening Service
• Antiinflammatory Activity Screening Service
• Probiotic Activity Screening Service
• Antidiabetic Activity Assay Service.

We provide in vitro and in vivo screening for hepatoprotective activity.

Fig.1 Hepatoprotective activity screening service. (CD BioGlyco)

Hepatoprotective activity screening assay in vitro typically uses liver cell lines that have been subjected to toxic injury. After treatment with marine glycans or glycoproteins, cytotoxicity, and cell viability are assessed using techniques such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) leakage assay, and caspase activity assay.

Hepatoprotective activity screening assay in vivo typically uses hepatotoxic drugs to induce liver injury in experimental animals and then administers marine glycans or glycoproteins to assess their protective effects. Key tests in the screening process include alanine aminotransferase (ALT) assay, aspartate aminotransferase (AST) assay, and alkaline phosphatase (ALP) assay. Increases in ALT, AST, and ALP levels are indicators of liver damage, hence these assays are used to measure the levels of these enzymes after treatment with the marine glycoprotein/glycan. In addition, we provide liver function tests such as total protein, albumin, and bilirubin content tests.

It is worth mentioning that the molecular docking and virtual screening services we provide also be used to predict interactions between protein targets in liver cells and marine glycoprotein/glycan molecules. Genetic studies provide further insights into the targets and mechanisms of action of the hepatoprotective glycoprotein/glycan.

Publication

Technology: ALT assay, AST assay, and ALP assay

Journal: Journal of Experimental Pharmacology

IF: 4.20

Published: 2020

Results: The authors evaluated the hepatoprotective activity of crude extracts and solvent fractions of Clutia abyssinica in mice. An 80% methanol extract has been shown to reduce both the absolute and relative liver weights in mice. Furthermore, it exhibited a suppressive effect on plasma levels of ALT, AST, and ALP at dosages of 200 and 400 mg/kg. These findings suggest that Clutia abyssinica possesses hepatoprotective properties.

Here are some of the results shown in this article:

Fig.2 Microphotograph of hematoxylin and eosin (H & E)-stained sections of liver. (Meharie, et al., 2020)

CD BioGlyco provides a variety of hepatoprotective activity screening services to examine the biological potency of these marine compounds against liver damage caused by various external stressors. We provide clients with professional in vivo and in vitro analysis to help clients solve scientific research problems. Please feel free to contact us if you are interested in our hepatoprotective activity screening service!